07:39am Saturday 19 August 2017

New computational model reveals novel possibilities for H. pylori treatment

Using the model, researchers identified an abnormal immune response linked to development of lesions during H. pylori infection of the stomach. Their findings may help clinicians pinpoint how best to treat such infections.

“This large-scale computational model of host responses to H. pylori infection combines cutting-edge approaches in computational modeling and experimental research to help elucidate immune responses to H. pylori,” said Raquel Hontecillas, co-director of the center, which is part of Virginia Tech’s Nutritional Immunology and Molecular Medicine Laboratory.

H. pylori  lives in the human gut and sometimes causes ulcers and cancers. Currently, doctors treat H. pylori infections with antibiotics that destroy the bacteria. However, H. pylori also can protect against diseases such as asthma, obesity and diabetes. Understanding how a harmless bacterial population becomes virulent and leads to disease has been difficult, but the computational model developed by the center researchers has led to new insights.

Based on results from experimental work with mouse models, the team of scientists built a computational simulation that can predict how and when infection begins and progresses. The model shows the position of cells during infection and accounts for the non-uniformity and randomness of immune responses. 

Using the computational model, laboratory researchers found that, although H. pylori may be responsible for starting an infection, abnormal immune responses can contribute to chronic ulcers or cancers.

“The knowledge gained from such models will accelerate the development of novel drugs and vaccines for H. pylori-associated diseases,” said Hontecillas. “The ultimate aim may not be to destroy H. pylori but to learn how to manipulate the interaction of the bacterium and host immune system to produce beneficial effects.”

The paper is available online through the Public Library of Science

The Center for Modeling Immunity to Enteric Pathogens is funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under Contract No. HHSN272201000056C. PI: Josep Bassaganya-Riera.

Dedicated to its motto, Ut Prosim (That I May Serve), Virginia Tech takes a hands-on, engaging approach to education, preparing scholars to be leaders in their fields and communities. As the commonwealth’s most comprehensive university and its leading research institution, Virginia Tech offers 215 undergraduate and graduate degree programs to more than 30,000 students and manages a research portfolio of $450 million. The university fulfills its land-grant mission of transforming knowledge to practice through technological leadership and by fueling economic growth and job creation locally, regionally, and across Virginia.



Share on:
or:

MORE FROM Infections

Health news